CINCINNATI, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that on September 8, 2014, through its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy"), received final approval for its Health and Safety Plan ("H & S Plan"). The approval was granted by the United States Environmental Protection Agency ("EPA") and the project subcontractor Chicago Bridge & Iron (NYSE: CBI ) ("CB & I"), which operates the EPA's Test & Evaluation ("T & E") Facility where the next phase of the commercial pilot will take place. This final approval, along with the already approved Quality Assurance Project Plan ("QA Plan"), will enable the Company to commence development scale pilot testing at the EPA T& E Facility. The facility is co-located with the Metropolitan Sewer District of Great Cincinnati's ("MSDGC") largest wastewater treatment plant, on the Mill Creek site, which flows directly into the Ohio river.
In March, Tauriga's Pilus subsidiary launched a five-phase commercial pilot study to customize a proprietary "wastewater to value" solution and to demonstrate feasibility of applying Pilus's synthetic biology platform to a large scale industrial sewage treatment plant. The vast majority of the Company's testing and resources to date have been allocated to the EPA T & E facility, where Tauriga is currently culturing the genetically enhanced bacteria ("Wastewater BactoBot") to be used in the Electrogenic Bioreactor ("EBR"). The Company has also inoculated a bioreactor with the Bots and will start generating wastewater remediation data within the next two weeks, followed by electricity generation test soon after.
Tauriga's CEO Dr. Stella M. Sung commented, "Receiving the approval to begin pilot testing at the EPA's T&E facility represents an important shift from benchtop scale science to development scale optimization. We look forward to analyzing the wastewater remediation results from our custom genetically engineered stains of bacterial, because this will inform and guide the next stages of our commercial pilot project, with our end goal of producing a large scale, effective and environmentally friendly solution for capturing value from organic pollutants."
Dr. Ting Lu, project manager at MSDGC expressed, "The Bactbot project has been making a lot of progress so far, and it can potentially solve many challenges that wastewater treatment has, such as treating high strength wastes while generating energy. MSDGC is excited about this technology and looks forward to its success."
Currently Tauriga is fabricating a minimum of five dedicated EBRs, which will have a 6-8 hour average retention time of the waste, leading to approximately 100 gallons per day of wastewater throughput. This wastewater will go through a full suite of testing including metrics such as Chemical Oxygen Demand ("COD"), Total Organic Carbon ("TOC"), Total Kjeldahl Nitrogen ("TKN"), Volatile Organic Compounds ("VOCs"), as well as others. During this process Tauriga will be fabricating additional reactors with the intention of having 200% to 300% of this capacity installed on a mobile demonstration unit that can be taken to wastewater generators all around Cincinnati and the surrounding area.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the synthetic biology space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 13, 2014, Tauriga acquired a California based topical cannabis cream company. Please visit the Company's corporate website at www.tauriga.com .
NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Tauriga Sciences, Inc.: Dr. Stella M. Sung, Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email:
